Vaxcyte, Inc. (NASDAQ:PCVX) Stock Holdings Lifted by Nicholas Investment Partners LP

Nicholas Investment Partners LP increased its position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 22.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,307 shares of the company’s stock after acquiring an additional 18,424 shares during the quarter. Nicholas Investment Partners LP owned 0.08% of Vaxcyte worth $8,211,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Whipplewood Advisors LLC purchased a new position in Vaxcyte during the 4th quarter valued at about $28,000. Smartleaf Asset Management LLC boosted its holdings in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock worth $33,000 after purchasing an additional 260 shares during the period. National Bank of Canada FI purchased a new position in Vaxcyte during the fourth quarter valued at approximately $41,000. Blue Trust Inc. increased its stake in Vaxcyte by 100.0% in the 4th quarter. Blue Trust Inc. now owns 742 shares of the company’s stock valued at $61,000 after buying an additional 371 shares during the period. Finally, Assetmark Inc. increased its stake in Vaxcyte by 77,500.0% in the 4th quarter. Assetmark Inc. now owns 776 shares of the company’s stock valued at $64,000 after buying an additional 775 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Activity

In other news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $73.27, for a total value of $586,160.00. Following the transaction, the chief operating officer now directly owns 154,931 shares in the company, valued at approximately $11,351,794.37. The trade was a 4.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 3.10% of the company’s stock.

Wall Street Analyst Weigh In

PCVX has been the topic of several research analyst reports. The Goldman Sachs Group lowered their price target on shares of Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a report on Tuesday, April 1st. Needham & Company LLC reissued a “buy” rating and set a $90.00 price objective on shares of Vaxcyte in a research report on Tuesday, April 8th. Cantor Fitzgerald initiated coverage on Vaxcyte in a research note on Tuesday, April 22nd. They issued an “overweight” rating on the stock. Bank of America cut their price target on Vaxcyte from $157.00 to $137.00 and set a “buy” rating for the company in a research note on Tuesday, April 1st. Finally, Evercore ISI upgraded Vaxcyte to a “strong-buy” rating in a report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average target price of $136.50.

Vaxcyte Price Performance

Shares of NASDAQ:PCVX opened at $30.05 on Wednesday. The stock has a market capitalization of $3.88 billion, a P/E ratio of -6.53 and a beta of 1.27. The business has a 50-day moving average of $44.91 and a two-hundred day moving average of $73.32. Vaxcyte, Inc. has a fifty-two week low of $27.66 and a fifty-two week high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). During the same quarter last year, the company earned ($0.85) earnings per share. As a group, research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.